853016-69-0

Upstream product

• 100-39-0 benzyl bromide 
• 72631-59-5 (3R,3aS,6R,6aR)-6-hydroxy-3-(4-methoxyphenyl)sulfonyloxyperhydrofuro[3,2-b]furan 
• 98-59-9 p-toluenesulfonyl chloride 
• 100-44-7 benzyl chloride 
• 641-74-7 1,4:3,6-dianhydro-D-mannitol 

Downstream Products

• 909400-45-9 1,4:3,6-dianhydro-2-azido-2-deoxy-5-O-(phenylmethyl)-D-glucitol 
• 909400-46-0 1,4:3,6-dianhydro-2-amino-2-deoxy-5-O-(phenylmethyl)-D-glucitol 
• 1355251-74-9 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-tryptophan)-D-glucitol 
• 1355251-75-0 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-carbobenzyloxy-L-proline-L-phenylalanine)-D-glucitol 
• 1355251-76-1 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-carbobenzyloxy-D-proline)-D-glucitol 
• 1355251-77-2 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(Nα-t-butoxycarbonyl-Nε-carbobenzyloxy-L-lysine)-D-glucitol 
• 1355251-78-3 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(Nα-t-butoxycarbonyl-N-tosyl-L-histidine)-D-glucitol 
• 1355251-80-7 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-carbobenzyloxyvaline-phenylalanine)-D-glucitol 
• 1355251-82-9 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-isoserine)-D-glucitol 
• 1355251-84-1 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-threonine)-D-glucitol 
• 1355251-86-3 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(Nα-t-butoxycarbonyl-Nδ,Nω-di-carbobenzyloxy-L-arginine)-D-glucitol 
• 1355251-64-7 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-proline)-D-glucitol 
• 1355251-68-1 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-L-valine)-D-glucitol 
• 1355251-70-5 1,4:3,6-dianhydro-5-O-(benzyl)-2-N-(N-t-butoxycarbonyl-O-benzyl-L-serine)-D-glucitol 

Relevant academic research and scientific papers

Novel peptide mimetics based on N-Protected amino acids derived from isomannide as potential inhibitors of NS3 serine protease of hepatitis C virus

Abstract: Hepatitis C virus (HCV) is among the most important flaviviruses. It has a serine protease which is important for viral replication and this enzyme constitutes a suitable target for new anti-retroviral drugs. Herein we disclose a series of amide and ester peptide mimetic inhibitors of serine proteases, all of them obtained via coupling reactions of isomannide derivatives with N-protected amino acids. The arginine derivative 19 showed 45% of inhibition of NS3/4A serine protease at 100 μM and molecular modeling studies had shown that 19 interacted with the active site of this enzyme.

The synthesis and applications of asymmetric phase-transfer catalysts derived from isomannide and isosorbide

We report herein the synthesis of various derivatives of isomannide and isosorbide. Alkylation on N-(diphenylmethylene)glycine tert-butyl ester show the new catalysts to be effective phase-transfer catalysts with moderately good enantioselectivity. The ef